S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.58 (-2.91%)
AAPL   141.90 (-2.39%)
MSFT   283.33 (-3.68%)
FB   340.54 (-3.69%)
GOOGL   2,716.00 (-3.74%)
TSLA   776.14 (-1.92%)
AMZN   3,315.96 (-2.64%)
NVDA   206.13 (-4.83%)
BABA   152.44 (+1.50%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.65 (-6.03%)
AMD   101.00 (-6.62%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.05 (-1.19%)
BA   218.64 (-2.46%)
AMC   36.98 (-5.90%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.58 (-2.91%)
AAPL   141.90 (-2.39%)
MSFT   283.33 (-3.68%)
FB   340.54 (-3.69%)
GOOGL   2,716.00 (-3.74%)
TSLA   776.14 (-1.92%)
AMZN   3,315.96 (-2.64%)
NVDA   206.13 (-4.83%)
BABA   152.44 (+1.50%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.65 (-6.03%)
AMD   101.00 (-6.62%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.05 (-1.19%)
BA   218.64 (-2.46%)
AMC   36.98 (-5.90%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.58 (-2.91%)
AAPL   141.90 (-2.39%)
MSFT   283.33 (-3.68%)
FB   340.54 (-3.69%)
GOOGL   2,716.00 (-3.74%)
TSLA   776.14 (-1.92%)
AMZN   3,315.96 (-2.64%)
NVDA   206.13 (-4.83%)
BABA   152.44 (+1.50%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.65 (-6.03%)
AMD   101.00 (-6.62%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.05 (-1.19%)
BA   218.64 (-2.46%)
AMC   36.98 (-5.90%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.58 (-2.91%)
AAPL   141.90 (-2.39%)
MSFT   283.33 (-3.68%)
FB   340.54 (-3.69%)
GOOGL   2,716.00 (-3.74%)
TSLA   776.14 (-1.92%)
AMZN   3,315.96 (-2.64%)
NVDA   206.13 (-4.83%)
BABA   152.44 (+1.50%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.65 (-6.03%)
AMD   101.00 (-6.62%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.05 (-1.19%)
BA   218.64 (-2.46%)
AMC   36.98 (-5.90%)
NASDAQ:MEIP

MEI Pharma Stock Forecast, Price & News

$2.83
-0.10 (-3.41 %)
(As of 09/28/2021 03:59 PM ET)
Add
Compare
Today's Range
$2.82
$2.89
50-Day Range
$2.52
$2.93
52-Week Range
$2.40
$4.57
Volume6,803 shs
Average Volume672,604 shs
Market Capitalization$318.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
30 days | 90 days | 365 days | Advanced Chart
Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.


MEI Pharma logo

About MEI Pharma

MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEIP
Previous Symbol
NASDAQ:MSHL
Employees
51
Year Founded
N/A

Sales & Book Value

Annual Sales
$25.53 million
Book Value
$0.37 per share

Profitability

Net Income
$-50,580,000.00
Net Margins
-198.06%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$318.88 million
Next Earnings Date
11/9/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.29 out of 5 stars

Medical Sector

256th out of 1,353 stocks

Pharmaceutical Preparations Industry

126th out of 666 stocks

Analyst Opinion: 4.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

Is MEI Pharma a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MEI Pharma stock.
View analyst ratings for MEI Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than MEI Pharma?

Wall Street analysts have given MEI Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MEI Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for MEI Pharma
.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings data on Tuesday, September, 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.12. The business earned $10.12 million during the quarter, compared to the consensus estimate of $5.18 million. MEI Pharma had a negative net margin of 198.06% and a negative trailing twelve-month return on equity of 80.62%.
View MEI Pharma's earnings history
.

How has MEI Pharma's stock been impacted by COVID-19 (Coronavirus)?

MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MEIP stock has increased by 85.8% and is now trading at $2.88.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MEIP?

7 brokers have issued 12-month target prices for MEI Pharma's shares. Their forecasts range from $8.00 to $20.00. On average, they expect MEI Pharma's share price to reach $11.00 in the next year. This suggests a possible upside of 281.9% from the stock's current price.
View analysts' price targets for MEI Pharma
or view top-rated stocks among Wall Street analysts.

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:
  • Daniel P. Gold, President, Chief Executive Officer & Director
  • David M. Urso, Chief Operating Officer & General Counsel
  • Brian G. Drazba, Chief Financial Officer & Secretary
  • Richard G. Ghalie, Chief Medical Officer
  • Tina C. Beamon, Chief Compliance Officer

What other stocks do shareholders of MEI Pharma own?

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (6.21%), BlackRock Inc. (6.10%), Wasatch Advisors Inc. (5.90%), Vanguard Group Inc. (4.67%), BVF Inc. IL (3.14%) and Woodline Partners LP (2.10%). Company insiders that own MEI Pharma stock include Brian G Drazba, Daniel P Phd Gold, Frederick W Driscoll and Thomas C Reynolds.
View institutional ownership trends for MEI Pharma
.

Which major investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Goldman Sachs Group Inc., Vanguard Group Inc., Bank of America Corp DE, Point72 Asset Management L.P., Connor Clark & Lunn Investment Management Ltd., and BVF Inc. IL.
View insider buying and selling activity for MEI Pharma
or view top insider-selling stocks.

Which major investors are buying MEI Pharma stock?

MEIP stock was purchased by a variety of institutional investors in the last quarter, including Woodline Partners LP, Altium Capital Management LP, First Light Asset Management LLC, Dimensional Fund Advisors LP, Millennium Management LLC, Panagora Asset Management Inc., Wells Fargo & Company MN, and Squarepoint Ops LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Daniel P Phd Gold, and Thomas C Reynolds.
View insider buying and selling activity for MEI Pharma
or or view top insider-buying stocks.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $2.88.

How much money does MEI Pharma make?

MEI Pharma has a market capitalization of $324.51 million and generates $25.53 million in revenue each year. The company earns $-50,580,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does MEI Pharma have?

MEI Pharma employs 51 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is www.meipharma.com.

Where are MEI Pharma's headquarters?

MEI Pharma is headquartered at 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 369-7100 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.